Tactile Systems Technology Inc

Tactile Systems Technology Inc (TCMD) Stock Analysis

$22.730

+0.211 (+0.93%)At close

Loading chart…
High
22.845
Open
22.530
VWAP
22.68
Volume
165.22K
Mkt Cap
274.93M
Low
22.450
Amount
3.75M
EV/EBITDA, TTM
12.32

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.

AI analysis of Tactile Systems Technology Inc (TCMD)

Buy

Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.

Analyst Ratings (6)

+39.33% upside
Buy
6 Buy
0 Hold
0 Sell
Current: 22.73
Low
28.00
Average
31.67
High
35.00

BTIG

2026-10-12

Price Target

$35

Buy

B. Riley

2026-05-07

Price Target

$36

Buy

BTIG

2026-05-05

Price Target

$40

Buy

BTIG

2026-02-18

Price Target

$38

Buy

B. Riley

2026-02-18

Price Target

$32

Neutral

Valuation Metrics

The current forward P/E ratio for Tactile Systems Technology Inc (TCMD) is 19.12, compared to its 5-year average forward P/E of 83.69.

Forward P/E

Fair
5Y Average P/E
83.69
Current P/E
19.12
Overvalued
468.20
Undervalued
-300.83

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-7.54
Current EV/EBITDA
12.32
Overvalued
75.76
Undervalued
-90.84

Forward P/S

Fair
5Y Average P/S
1.23
Current P/S
1.33
Overvalued
1.65
Undervalued
0.80

Alphio AI Price Scenarios for TCMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TCMD

$12.55

Scenario price

B

Base

Base · 50%TCMD

$12.06

Scenario price

B

Bear

Bear · 25%TCMD

$10.94

Scenario price

Whales holding TCMD

F

First Light Asset Management, LLC

+ HoldingTCMD

-11.88%

3M Return

Events Timeline

2026-08-10 (ET)

16:30:00

Tactile Medical Q2 Revenue $85.7M Beats Expectations

2026-05-04 (ET)

16:30:00

Tactile Medical Q1 Revenue $75.27M, Exceeds Expectations

16:30:00

Company Updates 2026 Revenue Outlook to $368 Million

2026-03-09 (ET)

08:30:00

Tactile Systems Appoints Andrea Pearson to Board of Directors

2026-02-17 (ET)

17:00:00

Tactile Systems Acquires LymphaTech for $6.8M

News

TCMD FAQ — answered by Alphio AI

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.

6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading